Biogen Income Statement (2009-2026) | BIIB

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)	2,775.00M	2,778.90M	2,733.80M	2,531.80M	2,589.10M	2,508.50M	2,544.00M	2,463.00M	2,456.00M	2,530.30M	2,386.30M	2,290.50M	2,464.90M	2,465.80M	2,454.70M	2,431.00M	2,645.50M	2,534.70M	2,279.40M	2,477.80M
Cost of Revenue (Quarter)	459.70M	511.80M	164.00M	275.00M	484.00M	469.50M	164.00M	662.80M	592.70M	659.60M	164.00M	542.20M	546.00M	638.70M	583.50M	629.30M	605.00M	674.40M	495.50M	661.00M
Gross Profit (Quarter)	2,315.30M	2,267.10M	2,569.80M	2,256.80M	2,105.10M	2,039.00M	2,380.00M	1,800.20M	1,863.30M	1,870.70M	2,222.30M	1,748.30M	1,918.90M	1,827.10M	1,871.20M	1,801.70M	2,040.50M	1,860.30M	1,783.90M	1,816.80M
Operating items
Amortization - Intangibles (Quarter)	604.10M	111.00M	68.10M	66.90M	67.50M	56.50M	175.00M	50.20M	52.90M	60.90M	76.60M	78.30M	86.90M	130.30M	151.20M	111.80M	130.90M	135.70M	136.60M	136.50M
Research & Development (Quarter)	585.10M	702.40M	699.50M	551.70M	528.60M	549.20M	601.60M	570.60M	584.20M	736.30M	75.00M	445.40M	505.40M	516.20M	513.30M	434.10M	399.00M	436.10M	509.40M	539.00M
Selling, General & Administrative (Quarter)	637.30M	654.10M	787.90M	634.90M	572.60M	563.30M	632.80M	605.00M	548.00M	788.20M	608.50M	581.50M	553.80M	588.40M	680.00M	572.50M	583.80M	594.80M	682.50M	607.30M
Restructuring Costs (Quarter)				27.70M	900.00M	7.10M	7.00M	7.10M	17.80M	11.50M	98.80M	11.50M	6.60M	6.80M	5.30M	35.30M	-0.70M	7.40M	6.60M	7.90M
Other Operating Expenses (Quarter)	96.40M	-502.90M	964.10M	7.10M	428.60M	56.00M	-12.20M	-69.40M	121.20M	-300.00M		-93.70M	-85.20M	-14.80M	166.00M	-68.40M		-34.10M		-19.70M
Operating Expenses (Quarter)	2,192.90M	2,487.80M	2,328.80M	2,184.40M	1,319.60M	1,137.40M	1,940.20M	2,024.70M	1,747.90M	2,671.50M	2,094.70M	1,825.70M	1,766.20M	2,014.80M	2,163.20M	2,119.80M	1,901.50M	1,977.40M	2,335.40M	2,100.10M
Operating Income (Quarter)	485.70M	794.00M	587.10M	610.70M	785.50M	901.60M	439.80M	-224.50M	115.40M	-800.80M	127.60M	-77.40M	152.70M	-187.70M	-292.00M	-318.10M	139.00M	-117.10M	-551.50M	-283.30M
EBIT (Quarter)	485.70M	794.00M	587.10M	610.70M	785.50M	901.60M	439.80M	-224.50M	115.40M	-800.80M	127.60M	-77.40M	152.70M	-187.70M	-292.00M	-318.10M	139.00M	-117.10M	-551.50M	-283.30M
Non-operating items
Other Non Operating Income (Quarter)
Non Operating Income (Quarter)	96.40M	-502.90M	-182.10M	-263.30M
Net income details
EBT (Quarter)	582.10M	291.10M	405.00M	347.40M	1,269.50M	1,371.10M	603.80M	438.30M	708.10M	-141.20M	291.60M	464.80M	698.70M	451.00M	291.50M	311.20M	744.00M	557.30M	-56.00M	377.70M
Tax Provisions (Quarter)	-409.10M	-25.90M	443.20M	125.60M	216.70M	236.20M	54.30M	50.70M	114.80M	-72.90M	42.70M	71.40M	115.10M	62.50M	24.80M	70.70M	109.20M	90.80M	-7.10M	58.20M
Profit After Tax (Quarter)	448.50M	329.20M	-20.50M	218.50M	1,058.00M	1,134.90M	465.10M	387.60M	591.60M	-68.30M	249.70M	393.40M	583.60M	388.50M	266.70M	240.50M	634.80M	466.50M	-48.90M	319.50M
Equity Income (Quarter)	45.00M	45.00M	45.00M	-3.30M	45.00M	3.40M
Net Income - Minority (Quarter)	-462.90M	-451.80M	-63.50M	21.60M	9.10M	8.70M	9.50M	9.60M	6.40M	4.10M
Income from Non-Controlling Interests (Quarter)	577.00M	-11.10M	-388.70M	-85.30M	0.70M	0.20M	-0.90M	-0.30M	1.70M	-0.20M	-0.80M
Income from Continuing Operations (Quarter)	991.20M	317.00M	-38.20M	221.80M	1,052.80M	1,134.90M	549.50M	387.60M	593.30M	-68.30M	248.90M	393.40M	583.60M	388.50M	266.70M	240.50M	634.80M	466.50M	-48.90M	319.50M
Consolidated Net Income (Quarter)	991.20M	317.00M	-38.20M	221.80M	1,052.80M	1,134.90M	549.50M	387.60M	593.30M	-68.30M	248.90M	393.40M	583.60M	388.50M	266.70M	240.50M	634.80M	466.50M	-48.90M	319.50M
Income towards Parent Company (Quarter)	528.30M	-134.80M	-101.70M	243.40M	1,061.90M	1,143.60M	559.00M	397.20M	599.70M	-64.20M	248.90M	393.40M	583.60M	388.50M	266.70M	240.50M	634.80M	466.50M	-48.90M	319.50M
Net Income towards Common Stockholders (Quarter)	528.30M	-134.80M	-101.70M	243.40M	1,061.90M	1,143.60M	559.00M	397.20M	599.70M	-64.20M	248.90M	393.40M	583.60M	388.50M	266.70M	240.50M	634.80M	466.50M	-48.90M	319.50M
Additional items
EPS (Basic) (Quarter)	3.00	2.22	2.51	2.06	7.25	7.86	3.84	2.69	4.09	-0.47	1.72	2.71	4.01	2.67	1.83	1.65	4.33	3.18	-0.33	2.17
EPS (Weighted Average and Diluted) (Quarter)	2.99	2.22	2.50	2.06	7.24	7.84	3.80	2.67	4.07	-0.47	1.71	2.70	4.00	2.66	1.83	1.64	4.33	3.17	-0.35	2.15
Shares Outstanding (Weighted Average) (Quarter)	149.70M	148.00M	149.10M	147.10M	146.50M	145.80M	145.30M	144.40M	144.60M	144.80M	144.70M	145.20M	145.60M	145.50M	145.60M	146.10M	146.50M	146.60M	146.50M	147.20M
Shares Outstanding (Diluted Average) (Quarter)	151.20M	148.60M	149.60M	147.60M	146.80M	146.20M	146.00M	145.20M	145.40M	145.50M	145.60M	145.90M	145.90M	146.10M	145.90M	146.60M	146.70M	147.10M	147.10M	148.40M
EBITDA (Quarter)	485.70M	794.00M	587.10M	610.70M	785.50M	901.60M	439.80M	-224.50M	115.40M	-800.80M	127.60M	-77.40M	152.70M	-187.70M	-292.00M	-318.10M	139.00M	-117.10M	-551.50M	-283.30M
Tax Rate (Quarter)	-70.28%	-8.90%	109.43%	36.15%	17.07%	17.23%	8.99%	11.57%	16.21%	51.63%	14.64%	15.36%	16.47%	13.86%	8.51%	22.72%	14.68%	16.29%	12.68%	15.41%

Research Tools

Biogen Income Statement (2009-2026) | BIIB

Create an account

Sign In

Reset Password